Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

PHASE4CompletedINTERVENTIONAL
Enrollment

1,133

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

September 5, 2021

Study Completion Date

September 5, 2021

Conditions
Influenza, HumanPneumonia, PneumococcalCovid19
Interventions
BIOLOGICAL

COVAX+IIV4; COVAX+PPV23

1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23

BIOLOGICAL

COVAX only (1st and 2nd dose)

1st dose: COVAX only; 2nd dose: COVAX only

BIOLOGICAL

IIV4 for the 1st dose and PPV23 for the 2nd dose

1st dose: IIV4 only; 2nd dose: PPV23 only

Trial Locations (3)

200336

Shanghai Municipal Center for Disease Control and Prevention, Shanghai

610041

Sichuan Center for Disease Control and Prevention, Chengdu

030012

Shanxi Provincial Center for Disease Control and Prevention, Taiyuan

All Listed Sponsors
collaborator

Chengdu Institute of Biological Products Co.,Ltd.

INDUSTRY

collaborator

Changchun Institute of Biological Products Co., Ltd.

INDUSTRY

collaborator

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

collaborator

Sichuan Center for Disease Control and Prevention

OTHER_GOV

collaborator

Shanghai Municipal Center for Disease Control and Prevention

OTHER

collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

lead

China National Biotec Group Company Limited

INDUSTRY

NCT04790851 - Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 | Biotech Hunter | Biotech Hunter